A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer

Published:2010-08 Issue:8 Volume:5 Page:1285-1288
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Blackhall Fiona H.,O'Brien Mary,Schmid Peter,Nicolson Marianne,Taylor Paul,Milenkova Tsveta,Kennedy Sarah J.,Thatcher Nick

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration;Wedge;Cancer Res,2002

2. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases;Carlomagno;Cancer Res,2002

3. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST);Natale;J Clin Oncol,2009

4. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL);de Boer;J Clin Oncol,2009

5. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC);Herbst;J Clin Oncol,2009

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?;Cancers;2024-08-28

2. Inhibitory effect of flavonoids on multidrug and toxin extrusion protein 1 function: Implications for food/herb–drug interaction and drug‐induced kidney injury;Journal of Applied Toxicology;2024-05-17

3. Research Methods and New Advances in Drug–Drug Interactions Mediated by Renal Transporters;Molecules;2023-07-06

4. Genetic variation in organic cation transporters and considerations in drug development;Expert Opinion on Drug Metabolism & Toxicology;2023-03-04

5. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2022-11